European equities traded in the US as American depositary receipts were heading moderately higher late Thursday morning, rising 0.32% to 1,451.76 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and Grifols (GRFS), which rose 2.5% and 2.1% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND), which was up 0.5%.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm Evaxion (EVAX), which dropped 8.9% and 6.5% respectively. They were followed by semiconductor company Sequans Communications (SQNS), which dropped 1.6%, accommodations booking company trivago (TRVG), which fell 1.5%, and petroleum refiner Equinor (EQNR), down 0.9%.

From the UK and Ireland, the gainers were led by biotech firms Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which advanced 7.9% and 5.5% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Adaptimmune Therapeutics (ADAP), which increased 4.4% and 1.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which lost 4% and 1.9% respectively. They were followed by education publisher Pearson (PSO) and tobacco company British American Tobacco (BTI), which were both off 0.8%.

Price: 1.45, Change: +0.04, Percent Change: +2.48